DK0531415T3 - Fremgangsmåde til behandling af alkoholisme med balmefen - Google Patents

Fremgangsmåde til behandling af alkoholisme med balmefen

Info

Publication number
DK0531415T3
DK0531415T3 DK91910595.7T DK91910595T DK0531415T3 DK 0531415 T3 DK0531415 T3 DK 0531415T3 DK 91910595 T DK91910595 T DK 91910595T DK 0531415 T3 DK0531415 T3 DK 0531415T3
Authority
DK
Denmark
Prior art keywords
balmfef
treating alcoholism
alcoholism
treating
alcoholics
Prior art date
Application number
DK91910595.7T
Other languages
Danish (da)
English (en)
Inventor
John D Sinclair
Harry Scheinin
Risto Lammintausta
Original Assignee
Orion Yhtymae Oy
Alko Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Yhtymae Oy, Alko Group Ltd filed Critical Orion Yhtymae Oy
Application granted granted Critical
Publication of DK0531415T3 publication Critical patent/DK0531415T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
DK91910595.7T 1990-06-04 1991-05-10 Fremgangsmåde til behandling af alkoholisme med balmefen DK0531415T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/532,424 US5086058A (en) 1990-06-04 1990-06-04 Method for treating alcoholism with nalmefene

Publications (1)

Publication Number Publication Date
DK0531415T3 true DK0531415T3 (da) 1996-12-09

Family

ID=24121726

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91910595.7T DK0531415T3 (da) 1990-06-04 1991-05-10 Fremgangsmåde til behandling af alkoholisme med balmefen

Country Status (19)

Country Link
US (1) US5086058A (fr)
EP (1) EP0531415B1 (fr)
JP (1) JP3059213B2 (fr)
AT (1) ATE145329T1 (fr)
AU (1) AU642748B2 (fr)
CA (1) CA2084519C (fr)
DE (1) DE69123247T2 (fr)
DK (1) DK0531415T3 (fr)
ES (1) ES2097209T3 (fr)
FI (1) FI925513A (fr)
GR (1) GR3022289T3 (fr)
HU (1) HU210637B (fr)
IE (1) IE77333B1 (fr)
LT (1) LT3893B (fr)
LV (1) LV10190B (fr)
NZ (1) NZ238391A (fr)
RU (1) RU2090190C1 (fr)
WO (1) WO1991018605A1 (fr)
ZA (1) ZA914185B (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
US6271239B1 (en) * 1992-04-13 2001-08-07 Regents Of The University Of Minnesota Delta opioid receptor-selective benzylidene-substituted morphinans
US5352680A (en) * 1992-07-15 1994-10-04 Regents Of The University Of Minnesota Delta opioid receptor antagonists to block opioid agonist tolerance and dependence
USRE36547E (en) * 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5298622A (en) * 1993-05-12 1994-03-29 Regents Of The University Of Minnesota Spiroindane opiate analogs
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
US5587381A (en) * 1995-03-27 1996-12-24 Sinclair; John D. Method for terminating methadone maintenance through extinction of the opiate-taking responses
WO1997018781A1 (fr) * 1995-11-20 1997-05-29 University Of Miami Procede pour traiter la dependance a la nicotine
US5878750A (en) * 1996-11-14 1999-03-09 Clemens; Anton H. Method of treating the syndrome of coronary heart disease risk factors in humans
US5780479A (en) * 1997-04-04 1998-07-14 Regents Of The University Of Minnesota Use of opioid antagonists to treat impulse-control disorders
US6277384B1 (en) 1997-12-22 2001-08-21 Euro-Celtique S.A. Opioid agonist/antagonist combinations
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
PL341309A1 (en) * 1997-12-22 2001-04-09 Euro Celtique Method of preventing overdosage of opioidic preparations
CA2392510A1 (fr) * 1999-11-30 2001-06-07 Corixa Corporation Compositions et methodes destinees au traitement et au diagnostic du cancer du sein
PT1255547E (pt) 2000-02-08 2008-11-24 Euro Celtique Sa Composições de libertação controlada contendo agonistas e antagonistas opióides
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US20040024004A1 (en) * 2001-05-04 2004-02-05 Sherman Barry M. Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
US6262062B1 (en) * 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6528520B2 (en) * 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6846831B2 (en) 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
US7879211B2 (en) * 2001-07-13 2011-02-01 Arkray, Inc. Analyzing instrument, lancet-integrated attachment for concentration measuring device provided with analyzing instrument, and body fluid sampling tool
PT1416842E (pt) * 2001-07-18 2009-03-31 Euro Celtique Sa Composições farmacêuticas de oxicodona e naloxona
WO2003013433A2 (fr) 2001-08-06 2003-02-20 Euro-Celtique S.A. Formulations d'antagoniste sequestre
PL367427A1 (en) 2001-08-06 2005-02-21 Euro-Celtique S.A. Opioid agonist formulations with releasable and sequestered antagonist
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030153590A1 (en) * 2001-08-14 2003-08-14 Oy Contral Pharma Ltd Method of treating alcoholism or alcohol abuse
MXPA04009713A (es) 2002-04-05 2005-01-11 Euro Celtique Sa Preparacion farmaceutica que contiene oxicodona y naloxona.
US7923454B2 (en) * 2002-05-17 2011-04-12 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US7501433B2 (en) * 2002-05-17 2009-03-10 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
ES2665999T3 (es) * 2002-05-31 2018-04-30 Titan Pharmaceuticals, Inc. Dispositivo polimérico implantable para la liberación sostenida de buprenorfina
DK1551372T3 (en) * 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES
PL1610791T3 (pl) 2003-03-31 2011-07-29 Titan Pharmaceuticals Inc Wszczepialne urządzenie polimerowe do przedłużonego uwalniania agonisty dopaminy
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
AU2004229551A1 (en) * 2003-04-14 2004-10-28 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
MY135852A (en) * 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US8017622B2 (en) * 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US20060009478A1 (en) * 2003-10-15 2006-01-12 Nadav Friedmann Methods for the treatment of back pain
EP1604666A1 (fr) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioides pour le traitement de la bronchopneumopathie chronique obstructive
EP1702558A1 (fr) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Procédé et dispositif pour évaluer la fonction de l'activité intestinale
WO2007149438A2 (fr) * 2006-06-19 2007-12-27 Alpharma, Inc. Compositions pharmaceutiques
ES2618500T3 (es) 2006-10-20 2017-06-21 Neurendo Pharma, Llc Método para restaurar el efecto incretina
WO2009088673A2 (fr) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Composition pharmaceutique
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
RU2495042C2 (ru) * 2008-04-24 2013-10-10 Янссен Фармацевтика Нв Пролекарства налмефена
KR101598138B1 (ko) * 2008-04-24 2016-02-29 얀센 파마슈티카 엔.브이. 날메펜 디에스테르 프로드럭
PE20110422A1 (es) * 2008-07-07 2011-07-01 Euro Celtique Sa Composicion farmaceutica que comprende antagonistas opioides
MY152279A (en) 2009-03-10 2014-09-15 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US20140005217A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
JP6419780B2 (ja) * 2013-04-17 2018-11-07 ハー・ルンドベック・アクチエゼルスカベット 睡眠障害患者の治療のためのナルメフェン
UA116567C2 (uk) 2013-07-23 2018-04-10 Євро-Селтік С.А. Комбінація оксикодону та налоксону для застосування в лікуванні болю у пацієнтів, які страждають від болю та захворювання, що призводить до дисбактеріозу кишечнику та/або підвищує ризик кишкової бактеріальної транслокації
SG10201809280PA (en) * 2014-04-22 2018-11-29 Otsuka Pharma Co Ltd Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
EP3215154B1 (fr) 2014-11-07 2020-01-29 Regents of the University of Minnesota Sels et compositions utiles pour le traitement de maladie
BR112018071705A2 (pt) * 2016-04-22 2019-02-19 Taiwanj Pharmaceuticals Co., Ltd. método de profilaxia ou tratamento de nafld, nash ou ash, uso de um composto de fórmula (i), e composto de fórmula (i)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
US4857533A (en) * 1988-12-15 1989-08-15 Baker Cummins Pharmaceuticals, Inc. Method of treatment for autoimmune diseases
US4863928A (en) * 1989-01-04 1989-09-05 Baker Cummins Pharmaceuticals, Inc. Method of treatment for arthritic and inflammatory diseases
US5096715A (en) * 1989-11-20 1992-03-17 Alko Ltd. Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist

Also Published As

Publication number Publication date
FI925513A0 (fi) 1992-12-04
AU7974091A (en) 1991-12-31
LV10190B (en) 1995-06-20
ES2097209T3 (es) 1997-04-01
NZ238391A (en) 1997-06-24
WO1991018605A1 (fr) 1991-12-12
LTIP1486A (en) 1995-09-25
JPH06506665A (ja) 1994-07-28
IE77333B1 (en) 1997-12-03
JP3059213B2 (ja) 2000-07-04
HU210637B (en) 1995-06-28
LT3893B (en) 1996-04-25
FI925513A (fi) 1992-12-04
US5086058A (en) 1992-02-04
CA2084519C (fr) 1999-02-09
HU9203835D0 (en) 1993-03-29
EP0531415A1 (fr) 1993-03-17
DE69123247T2 (de) 1998-01-15
EP0531415B1 (fr) 1996-11-20
RU2090190C1 (ru) 1997-09-20
CA2084519A1 (fr) 1991-12-05
HUT65523A (en) 1994-06-28
DE69123247D1 (de) 1997-01-02
GR3022289T3 (en) 1997-04-30
IE911888A1 (en) 1991-12-04
AU642748B2 (en) 1993-10-28
LV10190A (lv) 1994-10-20
ATE145329T1 (de) 1996-12-15
ZA914185B (en) 1992-07-29

Similar Documents

Publication Publication Date Title
DK0531415T3 (da) Fremgangsmåde til behandling af alkoholisme med balmefen
RU92016403A (ru) Способ лечения алкоголизма налмефеном
MXPA99001239A (es) Proceso mejorado para la produccion de bebidas alcoholicas que utilizan semilla de malta.
DE69522075T2 (de) Verfahren zum Herstellen von multifunktionellen, monolithisch-integrierten Schaltungsanordnungen
NO972438D0 (no) Plastkomponent, samt fremgangsmåte for dens fremstilling
NO960878D0 (no) Underjordisk tank med dobbelt komposittvegg, samt fremgangsmåte for dens fremstilling
MXPA02010036A (es) Polivinilbutirales entrelazados de alto peso molecular, metodo para la produccion de los mismos y su uso.
NO912182D0 (no) Fremgangsmaate for forbedring av formasjonspermeabilitet ved anvendelse av klordioksyd.
DK0659276T3 (da) Immunoassay til eftervisning af collagen eller collagenfragmenter
EP0629879A3 (fr) Procédé pour déterminer la profondeur d'un plan d'eau.
EP0446817A3 (en) Method for reducing the search complexity in analysis-by-synthesis coding
MXPA03000714A (es) Metodo para reducir exacerbaciones relacionadas con enfermedad de obstruccion pulmonar cronica.
MY119686A (en) Sequential distillation process for removing tetrahydroazepine from aminocapronitrile and/or hexamethylenediamine
GR3015586T3 (en) Process for producing fuel oil and gas by cracking waste rubber.
DK0556829T3 (da) Fremgangsmåde til formindskelse af cyklustiden ved flerhulheds-strækblæsestøbning
HUT60202A (en) Method for producing cork stopper
EP0536564A3 (en) Method to purify streptolysin o, intact streptolysin o obtainable by this method and its use
MD188B2 (ro) Procedeu de producere a extractului pentru bauturi alcoolice
NO950978D0 (no) Polyolefinbasert pigmentert blanding, samt fremgangsmåte for fremstilling av tilformede gjenstander med utgangspunkt i blandingen
RU2005191C1 (ru) Способ установки анкера
NO942473D0 (no) Fremgangsmåte for fremstilling av detonerende lunte med redusert, innstillbar detoneringshastighet
NO901503D0 (no) Prosess for separering av vann.
DE69029831D1 (de) Verfahren zur herstellung alkoholischer getränke
HUT66951A (en) Process for producing mannit by stereoselective hydrogenation on glas-supported copper-catalyst with the controlled pore volume
DE69401147D1 (de) Einspritzsteuerungs-Verfahren für Mehrpunkteinspritzung, Einspritzmotoren mit gesteuerter Zündung